Use the renal measure and units named by this source. Confirm product, indication, age, stable versus changing kidney function, and exact dialysis modality. The selected summary is not a complete prescribing monograph. Renal method and dosing checklist
Choose a source to read (2)
Display order is not a clinical ranking. Date of retrieval is not the label revision date. Sources are never merged into one regimen. Other sources and conflicts remain below.
1 additional source qualifications - review before use
Verify the presentation. Intravenous daratumumab and the subcutaneous daratumumab/hyaluronidase combination have different administration instructions.
Before applying: Apply only to the stated formulation, indication and renal population.
Also check: Darzalex Faspro - product and source limitations
Official source
Darzalex Faspro - labeled renal guidance
Renal action and limits
Daratumumab/hyaluronidase-fihj (Darzalex Faspro), subcutaneous injection Renal impairment categories as defined by the cited product label
Action or finding
Renal impairment had no clinically important effect on daratumumab disposition in the cited population analysis.
Limits and monitoring
Verify the presentation. Intravenous daratumumab and the subcutaneous daratumumab/hyaluronidase combination have different administration instructions.
Before use
Apply only to the stated formulation, indication and renal population.
DailyMed SPL version 34, posted Oct 14, 2026 | Selected sections checked 2026-11-07. Independent clinical review pending.
Renal impairment categories as defined by the cited product label
Source revision
DailyMed SPL version 34, posted Oct 14, 2026
Retrieved
2026-11-07 (not the revision date)
Pharmacokinetic observation only. A drug-exposure observation is not itself a dose recommendation.
Renal guidance: 12.3 Pharmacokinetics
Renal impairment had no clinically important effect on daratumumab disposition in the cited population analysis. Verify the presentation. Intravenous daratumumab and the subcutaneous daratumumab/hyaluronidase combination have different administration instructions.
Source revision: DailyMed SPL version 34, posted Oct 14, 2026 | Retrieved: 2026-11-07. Retrieval date is not the revision date.
Choose a source to jump directly to its locally stored result. Qualitative precautions and evidence gaps remain visible even when no numerical clearance schedule is supplied.
Locate a word or phrase within this drug's source summaries. Choose all sources or one source to focus the search. The selection never hides warnings or source text, changes a dose, or proves that a renal finding is absent.
Find:
Enter at least two characters. This in-page search is processed in your browser. Do not enter patient identifiers; advertising scripts also run on this page.
All source summaries, original wording and provenance
Before applying a renal protocol
Check the setting. Compare whole sources.
No patient-specific dose is calculated. Context choices only display reminders; they do not validate, hide or change any regimen.
Share a reproducible source review
Choose sources below, then open a print-ready comparison with product scope, renal method, dates and cautions. Links can pin the exact local cards; they never contain patient values or choose a dose.
Select two distinct source versions. The complete stored summaries will appear below.
Source-by-source comparison
These protocols may disagree and may apply to different settings. This view does not reconcile or endorse a patient-specific regimen.
Build a source-review outline for documentation
This creates a blank decision outline with the source identities you select, not a dose recommendation or completed clinical assessment. No patient fields are collected, saved or sent. Complete the clinical decisions in your approved documentation system.
Choose one or two sources above or use the source checkboxes below.
Renal-context checklist: population, kidney trend and dialysis
These prompts are a reading aid, not a prescription checklist or proof that all requirements have been met. No selections are stored or sent to a server.
Read the exact source scope, renal metric and date before selecting a row. No applicability assessment has been performed.
These are specific issues found during source review, not an automated judgment that one source is universally correct. A label mirror and its original label are not independent evidence.
Source scope / renal recommendation differences
Darzalex Faspro - product and source limitations
Verify the presentation. Intravenous daratumumab and the subcutaneous daratumumab/hyaluronidase combination have different administration instructions.
How to use this: Apply only to the stated formulation, indication and renal population.
Choose a source, then jump to its renal or dialysis section. These links locate stored text; they do not merge regimens or certify that sources agree.
Independent clinical review is pending. These selected summaries are not an approved institutional dosing protocol. Confirm the exact product, the complete current source and local policy before use.
No dialysis or renal heading shown? Read the complete source summary. Absence of a heading is not evidence that dose adjustment is unnecessary.
Compare or copy source versions
All content below is stored locally. Read a whole source version; do not combine its dose with another source's interval, renal metric or dialysis assumptions.
Exact product and population matter. This added page contains locally stored, source-specific clinical summaries. Historical handbook information, when present, is identified separately and may conflict with U.S. labeling. Confirm indication, population, kidney-function method, monitoring and the full prescribing information before applying a regimen.
Renal method: Renal impairment categories as defined by the cited product label Source date: DailyMed SPL version 34, posted Oct 14, 2026 Retrieved: 2026-11-07
Pharmacokinetic observation only. A drug-exposure observation is not itself a dose recommendation.
Renal impairment had no clinically important effect on daratumumab disposition in the cited population analysis. Verify the presentation. Intravenous daratumumab and the subcutaneous daratumumab/hyaluronidase combination have different administration instructions.
Renal method: Use the renal measure explicitly present in the RX passage. Source date: Mirror revision not established in the reviewed passage. Retrieved: 2026-11-07
Label mirror, not independent corroboration. This is selected locally stored RX List content. Full monograph import and current official-label review are not implied.
Pharmacokinetic observation only. A drug-exposure observation is not itself a dose recommendation.
Additional summaries stored on this page: 1 official-label, 1 RX List, 0 professional, 0 handbook. Empty additional-source groups are not shown. A missing layer is not a no-adjustment recommendation.
Source-section locators identify where retained content came from. A source-section identifier does not assert that every numeric statement has been independently corroborated. The local text hash is not a hash of original HTML, an FDA PDF or SPL XML.
This page is an additional exact-product entry, not a recovered GlobalRPh monograph. Its primary scope text and separately attributed clinical summaries are locally included.
